0
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found

      Level of Inositol-1,4,5-Trisphosphate after Cholinergic Stimulation of Human Lymphocytes

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The interrelationships between the immune and neurohormonal system are the subject of this work. In this context, the formation of inositol-1,4,5-tris-phosphate (IP<sub>3</sub>) in response to cholinergic stimulation was studied in activated human peripheral blood mononuclear cells (PBMC) and lymphocytes from the lymphoblastoid cell lines Jurkat and Raji. The cells were stimulated with mitogen and then treated with either the cholinergic agonist carbachol or nicotine. The radioreceptor assay was used to determine IP3. Cholinergic agonists increased the level of IP<sub>3</sub>in all studied lymphocytes. Maximal level of IP<sub>3</sub>was observed in PBMC after stimulation with nicotine, whereas in Raji cells IP<sub>3</sub>level significantly increased after stimulation with carbachol and nicotine. These results indicate that the effect of stimulation of cholinergic receptors present on the activated human lymphocytes appears to be followed by an enhancement in the rate of polyphosphoinositide hydrolysis.

          Related collections

          Author and article information

          Journal
          NIM
          Neuroimmunomodulation
          10.1159/issn.1021-7401
          Neuroimmunomodulation
          S. Karger AG
          1021-7401
          1423-0216
          1995
          1995
          22 May 1995
          : 2
          : 1
          : 25-30
          Affiliations
          Department of Pathophysiology, Institute of Rheumatology, Warsaw, Poland
          Article
          96831 Neuroimmunomodulation 1995;2:25–30
          10.1159/000096831
          7614257
          © 1995 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          Page count
          Pages: 6
          Categories
          Original Paper

          Comments

          Comment on this article